All In Biotech

Investigational drug · Phase 2

TY-302

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Metastatic Castration-resistant Prostate Cancer (mCRPC).

Phase 2

Last checked: Nov 19, 2026Latest source record: Aug 5, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

2

Any phase or sponsor naming "TY-302"

First trial start

2025

Aug 2025

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "TY-302", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Metastatic Castration-resistant Prostate Cancer (mCRPC)

Approved drugs for the same conditions: Prostate cancer · Oncology · Kidney and urology

Largest trials

Live from ClinicalTrials.gov: studies naming "TY-302" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Metastatic Castration-resistant Prostate Cancer (mCRPC)

  • YL201Tambotatug Pelitecan, Tam-PeliPhase 311 trials

    MediLink Therapeutics (Suzhou) Co., Ltd. · Advanced Solid Tumor, Small Cell Lung Cancer, Metastatic Pancreatic Cancer

  • OpevesostatMK-5684, ODM-208Phase 37 trials

    Merck & Co. · Prostate Cancer Metastatic, Malignant Neoplasm, Metastatic Castration-resistant Prostate Cancer (mCRPC)

  • PasritamigJNJ-78278343Phase 34 trials

    Johnson & Johnson (Janssen) · Solid Tumor, Metastatic Castration-resistant Prostatic Neoplasms, Metastatic Castration-resistant Prostate Cancer (mCRPC)

  • ARDTPhase 32 trials

    Novartis · Metastatic Castration-Resistant Prostate Cancer (mCRPC), Prostatic Neoplasms

  • FuzuloparibPhase 31 trial

    Jiangsu HengRui Medicine Co., Ltd. · Metastatic Castration-Resistant Prostate Cancer (mCRPC)

  • REGN5678NezastomigPhase 23 trials

    Regeneron · Metastatic Castration-resistant Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC)

  • GI-102Phase 22 trials

    GI Innovation, Inc. · Advanced Solid Tumor, Metastatic Solid Tumor, Soft Tissue Sarcoma (STS)

  • REGN4336Phase 22 trials

    Regeneron · Metastatic Castration-resistant Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC)

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.